Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833121 | 0.92 | POLG (0.49) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL15837277 | 0.92 | POLG (0.49) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL20754367 | 0.90 | POLG (0.47) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL19590226 | 0.89 | POLG (0.51) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL18877332 | 0.87 | POLG (0.49) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL16368345 | 0.87 | POLG (0.49) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL16374232 | 0.87 | POLG (0.49) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL15833360 | 0.86 | POLG (0.48) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL16374050 | 0.86 | POLG (0.48) | POLGPNPFUT5POLBTGM2 | |
| SCHEMBL20693182 | 0.84 | POLG (0.51) | POLGPNPFUT5POLBTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683320-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190085011-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683320-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C2 | POLG 390/4885PNP 1/4885FUT5 253/4885 |
| US-20190085011-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | POLG 390/4885PNP 1/4885FUT5 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.